See more : GelStat Corporation (GSAC) Income Statement Analysis – Financial Results
Complete financial analysis of Sonnet BioTherapeutics Holdings, Inc. (SONN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sonnet BioTherapeutics Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- XS Financial Inc. (XSHLF) Income Statement Analysis – Financial Results
- Swedish Orphan Biovitrum AB (publ) (BIOVF) Income Statement Analysis – Financial Results
- Nuveen Churchill Direct Lending Corp. (NCDL) Income Statement Analysis – Financial Results
- Alterity Therapeutics Limited (ATH.AX) Income Statement Analysis – Financial Results
- Zhejiang Founder Motor Co., Ltd. (002196.SZ) Income Statement Analysis – Financial Results
Sonnet BioTherapeutics Holdings, Inc. (SONN)
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.63K | 147.81K | 349.94K | 483.63K | 0.00 | 40.61M | 30.73M | 41.43M | 41.70M | 42.40M | 0.00 | 17.50M | 6.88M | 1.46M | 136.30K | 684.68K | 234.06K |
| Cost of Revenue | 0.00 | 11.81M | 93.26K | 16.63M | 58.31K | 7.93M | 29.94M | 39.41M | 38.38M | 14.04M | 0.00 | 0.00 | 2.76M | 360.81K | 11.08K | 684.68K | 234.06K |
| Gross Profit | 18.63K | -11.67M | 256.69K | -16.15M | -58.31K | 32.68M | 791.11K | 2.03M | 3.33M | 28.36M | 0.00 | 17.50M | 4.12M | 1.10M | 125.22K | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | -7,893.43% | 73.35% | -3,339.55% | 0.00% | 80.47% | 2.57% | 4.89% | 7.98% | 66.89% | 0.00% | 100.00% | 59.87% | 75.35% | 91.87% | 0.00% | 0.00% |
| Research & Development | 5.74M | 11.81M | 21.44M | 16.63M | 9.88M | 2.20M | 154.72K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.13M | 7.13M | 8.58M | 8.94M | 7.53M | 2.51M | 363.88K | 4.55M | 5.80M | 7.42M | 0.00 | 0.00 | 2.62M | 1.25M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.50M | 0.00 | 145.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.13M | 7.13M | 8.58M | 8.94M | 7.53M | 2.51M | 3.86M | 4.55M | 5.95M | 7.42M | 0.00 | 0.00 | 2.62M | 1.25M | 935.11K | 2.24M | 2.27M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 125.50K | 0.00 | 11.05M | 11.05M | 5.19M | 3.45M | 3.36M | 0.00 | -23.29M | 0.00 | 0.00 | 0.00 | -1.12M | -1.14M |
| Operating Expenses | 11.87M | 18.94M | 30.02M | 25.57M | 17.41M | 4.71M | 3.86M | 4.55M | 5.95M | 10.78M | 0.00 | -23.29M | 2.62M | 1.25M | 935.11K | 1.12M | 1.14M |
| Cost & Expenses | 11.87M | 18.94M | 30.02M | 25.57M | 17.41M | 4.71M | 33.80M | 43.95M | 44.32M | 24.82M | 0.00 | -23.29M | 9.75M | 2.18M | 946.19K | 1.13M | 1.15M |
| Interest Income | 0.00 | 0.00 | 0.00 | 15.00 | 20.68K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.54K | 46.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 20.68K | 162.87K | 381.68K | -2.59M | -2.35M | -3.47M | 0.00 | 0.00 | -474.93K | -180.83K | 140.02K | 33.91K | 20.49K |
| Depreciation & Amortization | 0.00 | 75.75K | 93.26K | 95.16K | 58.31K | 3.54M | 1.82M | 2.28M | 2.34M | 2.36M | 0.00 | 0.00 | 383.45K | 87.62K | 11.08K | 11.48K | 11.20K |
| EBITDA | -11.85M | -18.72M | -29.58M | -24.99M | -24.24M | -13.15M | -3.71M | -2.93M | 541.15K | -2.73M | 0.00 | -3.91M | -3.24M | -1.18M | -878.82K | -376.05K | -2.21M |
| EBITDA Ratio | -63,617.91% | -12,663.22% | -8,463.34% | -5,163.13% | 0.00% | -11.59% | -4.08% | -0.57% | -0.67% | -31.68% | 0.00% | -33.13% | -47.06% | -80.75% | -644.76% | -54.92% | -942.91% |
| Operating Income | -11.85M | -18.79M | -29.67M | -25.09M | -24.24M | -4.71M | -3.07M | -2.52M | -2.62M | -11.49M | 0.00 | -5.80M | -2.87M | -714.31K | -809.89K | -444.49K | -949.99K |
| Operating Income Ratio | -63,617.91% | -12,714.47% | -8,478.34% | -5,187.36% | 0.00% | -11.59% | -9.99% | -6.08% | -6.28% | -27.10% | 0.00% | -33.13% | -41.69% | -48.80% | -594.19% | -64.92% | -405.88% |
| Total Other Income/Expenses | 4.41M | -40.08K | -52.48K | 103.48K | -27.34K | -162.87K | -7.38M | -5.29M | -1.53M | 3.59M | 0.00 | 508.78K | -505.46K | -379.90K | -220.03K | -369.21K | -1.29M |
| Income Before Tax | -7.44M | -18.83M | -29.72M | -24.98M | -24.27M | -4.87M | -8.07M | -7.81M | -4.15M | -14.32M | 0.00 | -5.96M | -3.38M | -1.09M | -1.03M | -813.70K | -2.24M |
| Income Before Tax Ratio | -39,929.30% | -12,741.58% | -8,493.34% | -5,165.97% | 0.00% | -11.99% | -26.26% | -18.85% | -9.95% | -33.78% | 0.00% | -34.07% | -49.04% | -74.75% | -755.62% | -118.84% | -956.45% |
| Income Tax Expense | 0.00 | 0.00 | 52.48K | 22.03K | 6.80M | 162.87K | -701.22K | -644.43K | 198.46K | -187.57K | 0.00 | 0.00 | 19.21K | 14.61K | 0.00 | 0.00 | 0.00 |
| Net Income | -7.44M | -18.83M | -29.77M | -25.01M | -31.06M | -5.03M | -6.85M | -6.79M | -9.08M | -12.14M | 0.00 | -5.96M | -3.17M | -1.10M | -1.01M | -813.70K | -2.24M |
| Net Income Ratio | -39,929.30% | -12,741.58% | -8,508.34% | -5,170.52% | 0.00% | -12.40% | -22.30% | -16.40% | -21.77% | -28.63% | 0.00% | -34.07% | -46.01% | -75.38% | -742.16% | -118.84% | -956.45% |
| EPS | -11.35 | -18.14 | -150.79 | -313.76 | -1.02K | -5.78K | -15.59K | -21.55K | -33.50K | -42.60K | 0.00 | -68.28K | -1.25 | -0.47 | -175.20K | -540.70K | -1.57M |
| EPS Diluted | -11.35 | -18.14 | -150.79 | -313.76 | -1.02K | -5.78K | -15.59K | -21.55K | -33.50K | -42.60K | 0.00 | -68.28K | -1.25 | -0.47 | -175.20K | -540.70K | -1.57M |
| Weighted Avg Shares Out | 655.24K | 1.04M | 197.46K | 79.70K | 30.59K | 871.48 | 439.58 | 315.31 | 270.92 | 284.91 | 191.00 | 87.31 | 2.54M | 2.37M | 5.77 | 1.50 | 1.42 |
| Weighted Avg Shares Out (Dil) | 655.24K | 1.04M | 197.46K | 79.70K | 30.59K | 871.48 | 439.58 | 315.31 | 270.92 | 284.91 | 191.00 | 87.31 | 2.54M | 2.37M | 5.77 | 1.50 | 1.42 |
Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series
PRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced that it will participate in the Virtual Investor Closing Bell Series on Monday,...
Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer
Preclinical data has demonstrated the potential of SON-1210, the first albumin-binding bifunctional IL-12/IL-15 fusion protein, for solid tumor immunotherapy
Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
Ongoing progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC)
Sonnet BioTherapeutics (NASDAQ:SONN) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
Watch the "What This Means" segment here FRENCHTOWN, NJ / ACCESSWIRE / July 24, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Virtual Investor "What This Means" segment featuring Sonnet BioTherapeutics,...
Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study
PRINCETON, N.J., July 24, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced encouraging data from the Phase 1b portion of its Phase 1b/2a clinical trial evaluating...
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that the SB221 study of SON-1010 (recombinant human Interleukin-12 linked to Sonnet's fully-human...
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher levelsPatients have received up to 25 cycles of SON-1010 as monotherapy and 10 cycles of SON-1010 with atezolizumab (Tecentriq®) without...
Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
Published Phase 1 data of SON-1010 in Frontiers in Immunology demonstrating the safety and tolerability of the F H AB-derived Interleukin 12 in healthy volunteers Announced early safety data from the company's Phase 1b/2a clinical trial of SON-080 in patients...
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference
PRINCETON, NJ / ACCESSWIRE / May 6, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a biopharmaceutical company developing innovative targeted biologic drugs, will be participating in the EF Hutton Annual Global Conference, which will take place on May 15, 2024...
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference
Minneapolis, Minnesota--(Newsfile Corp. - May 3, 2024) - Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a biopharmaceutical company developing innovative targeted biologic drugs, will be participating in the EF Hutton Annual Global Conference, which will take place on May 15, 2024...
Source: https://incomestatements.info
Category: Stock Reports